Eversept Partners LP Has $76.94 Million Stock Holdings in Natera, Inc. $NTRA

Eversept Partners LP grew its stake in Natera, Inc. (NASDAQ:NTRA) by 15.0% in the first quarter, Holdings Channel.com reports. The institutional investor owned 384,713 shares of the medical research company’s stock after buying an additional 50,220 shares during the quarter. Natera makes up approximately 4.1% of Eversept Partners LP’s portfolio, making the stock its 5th biggest position. Eversept Partners LP’s holdings in Natera were worth $76,939,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Maverick Capital Ltd. lifted its holdings in shares of Natera by 24.1% during the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after acquiring an additional 227,605 shares during the last quarter. Quantinno Capital Management LP increased its stake in Natera by 8.9% in the first quarter. Quantinno Capital Management LP now owns 61,550 shares of the medical research company’s stock valued at $12,310,000 after acquiring an additional 5,007 shares during the last quarter. OMERS ADMINISTRATION Corp increased its stake in Natera by 28.2% in the first quarter. OMERS ADMINISTRATION Corp now owns 11,126 shares of the medical research company’s stock valued at $2,225,000 after acquiring an additional 2,445 shares during the last quarter. Lombard Odier Asset Management Switzerland SA purchased a new stake in Natera during the first quarter valued at about $367,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Natera during the first quarter valued at about $1,610,000. Institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on NTRA. Robert W. Baird set a $265.00 price objective on Natera in a report on Friday, May 8th. Guggenheim raised their price objective on Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Piper Sandler restated an “overweight” rating and issued a $249.00 target price on shares of Natera in a research report on Tuesday, May 12th. Finally, Barclays cut their target price on Natera from $280.00 to $260.00 and set an “overweight” rating for the company in a research note on Wednesday, June 24th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $267.83.

Insider Transactions at Natera

In related news, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the sale, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. This represents a 27.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Herm Rosenman sold 16,530 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director owned 4,250 shares in the company, valued at approximately $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 167,171 shares of company stock valued at $37,239,209. 5.05% of the stock is currently owned by corporate insiders.

Natera Stock Down 1.5%

Natera stock opened at $258.03 on Tuesday. The firm has a fifty day simple moving average of $242.06 and a two-hundred day simple moving average of $221.57. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $288.04. The company has a market capitalization of $36.95 billion, a PE ratio of -158.30 and a beta of 1.51.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.